Sumitomo Pharma Co., Ltd. (DNPUF)
| Market Cap | 4.67B +136.0% |
| Revenue (ttm) | 2.89B +21.6% |
| Net Income | 702.17M |
| EPS | 1.77 |
| Shares Out | n/a |
| PE Ratio | 6.65 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,321 |
| Average Volume | 2,238 |
| Open | 12.00 |
| Previous Close | n/a |
| Day's Range | 11.80 - 12.60 |
| 52-Week Range | 4.00 - 19.20 |
| Beta | 0.54 |
| RSI | 49.12 |
| Earnings Date | May 13, 2026 |
About Sumitomo Pharma
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson’s disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has coll... [Read more]
Full Company ProfileNews
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Shares of Japan's Sumitomo Pharma fell over 12%. Japanese government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease.